Baseline characteristics of participants enrolled in the empagliflozin cardiovascular outcome trial (EMPA-REG OUTCOME™) in patients with type 2 diabetes
B Zinman, S Inzucchi, J Lachin, C Wanner, R Ferrari, D Fitchett, E Bluhmki, J Kempthorne-Rawson, J Newman, OE Johansen, HJ Woerle, UC Broedl · Diabetologie und Stoffwechsel · 2014 · Heft 05
Bibliografische Angaben
Zusammenfassung
Background, material and methods: The EMPA-REG OUTCOME™ trial (NCT01131676) will investigate the effect of the sodium glucose cotransporter 2 inhibitor empagliflozin 10 mg or 25 mg od compared with placebo, upon a background of optimal standard of care, on cardiovascular (CV) outcomes in patients with type 2 diabetes mellitus (T2DM) at increased CV risk. The study is a double-blind, double-dummy and event-driven (691 CV deaths, non-fatal myocardial infarctions or non-fatal strokes) trial, powered for CV non-inferiority and superiority. Results: Between September 2010 and April 2013, 7063 patients were randomised…
